On November 7, 2023 PharmaMar (MSE:PHM) has announced today that its licensing partner, Adium Pharma, reported that it has received full approval for commercialization for Zepzelca (lurbinectedin) from the Ministry of Health of Peru for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy (Press release, PharmaMar, NOV 7, 2023, View Source [SID1234637062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive and platinum-resistant disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In March 2021, PharmaMar and Adium Pharma signed a licensing agreement for lurbinectedin in Latin America. The Peruvian approval of lurbinectedin has been preceded by the approval in Mexico and Ecuador.

With this approval, lurbinectedin is now authorized in 14 countries worldwide.

SCLC accounted for up to 15% of all lung cancer cases[1]. Most SCLC patients are already at the advanced stage upon diagnosis, resulting in poor prognosis.

On November 7, 2023 PharmaMar (MSE:PHM) has announced today that its licensing partner, Adium Pharma, reported that it has received full approval for commercialization for Zepzelca (lurbinectedin) from the Ministry of Health of Peru for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy (Press release, PharmaMar, NOV 7, 2023, View Source [SID1234637062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive and platinum-resistant disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In March 2021, PharmaMar and Adium Pharma signed a licensing agreement for lurbinectedin in Latin America. The Peruvian approval of lurbinectedin has been preceded by the approval in Mexico and Ecuador.

With this approval, lurbinectedin is now authorized in 14 countries worldwide.

SCLC accounted for up to 15% of all lung cancer cases[1]. Most SCLC patients are already at the advanced stage upon diagnosis, resulting in poor prognosis.

On November 7, 2023 PharmaMar (MSE:PHM) has announced today that its licensing partner, Adium Pharma, reported that it has received full approval for commercialization for Zepzelca (lurbinectedin) from the Ministry of Health of Peru for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy (Press release, PharmaMar, NOV 7, 2023, View Source [SID1234637062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive and platinum-resistant disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In March 2021, PharmaMar and Adium Pharma signed a licensing agreement for lurbinectedin in Latin America. The Peruvian approval of lurbinectedin has been preceded by the approval in Mexico and Ecuador.

With this approval, lurbinectedin is now authorized in 14 countries worldwide.

SCLC accounted for up to 15% of all lung cancer cases[1]. Most SCLC patients are already at the advanced stage upon diagnosis, resulting in poor prognosis.

On November 7, 2023 Race Oncology Ltd (ASX:RAC) reported that it has fielded "impressive" Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial (Press release, Race Oncology, NOV 7, 2023, View Source [SID1234637061]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients.

On November 7, 2023 Race Oncology Ltd (ASX:RAC) reported that it has fielded "impressive" Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial (Press release, Race Oncology, NOV 7, 2023, View Source [SID1234637061]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients.